Other formats:
BibTeX
LaTeX
RIS
@article{1159188,
author = {Szturz, Petr and Adam, Zdeněk and Rehak, Zdenek and Koukalová, Renata and Křen, Leoš and Moulis, Mojmír and Krejčí, Marta and Mayer, Jiří},
article_location = {Roma},
article_number = {5},
doi = {http://dx.doi.org/10.1700/1377.15326},
keywords = {Langerhans cell histiocytosis; Erdheim-Chester disease; angiomatosis; Castleman disease},
language = {eng},
issn = {0300-8916},
journal = {Tumori},
title = {Salvage lenalidomide in four rare oncological diseases},
url = {http://www.tumorionline.it/articoli.php?archivio=yes&vol_id=1377&id=15326},
volume = {99},
year = {2013}
}
TY - JOUR
ID - 1159188
AU - Szturz, Petr - Adam, Zdeněk - Rehak, Zdenek - Koukalová, Renata - Křen, Leoš - Moulis, Mojmír - Krejčí, Marta - Mayer, Jiří
PY - 2013
TI - Salvage lenalidomide in four rare oncological diseases
JF - Tumori
VL - 99
IS - 5
SP - "e251"-"e256"
EP - "e251"-"e256"
PB - PENSIERO SCIENTIFICO EDITOR
SN - 03008916
KW - Langerhans cell histiocytosis
KW - Erdheim-Chester disease
KW - angiomatosis
KW - Castleman disease
UR - http://www.tumorionline.it/articoli.php?archivio=yes&vol_id=1377&id=15326
N2 - In rare disorders, there are often no standard therapy recommendations. Patients with refractory disease may require novel experimental approaches. Applied as second- up to fourth-line treatment, lenalidomide (10-25 mg perorally on days 1-21 in a 28-day cycle) was used in our cohort of four adult patients with aggressive, multisystem and relapsing diseases. Complete and long-lasting remissions (more than 1 year, no maintenance therapy) were achieved in patients with Langerhans cell histiocytosis (11 cycles, combination with dexamethasone and etoposide, consolidated by allogeneic blood stem cell transplant) and plasma-cell Castleman disease (15 cycles, monotherapy). Mixed response with complete disappearance of brain infiltrates was reached in Erdheim-Chester disease (6 cycles, monotherapy) and gastrointestinal bleeding was well controlled in multiple angiomatosis (9 cycles, combination with thalidomide). For disease activity evaluation each patient underwent fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography scan imaging, which was complemented by clinical and laboratory investigations.
ER -
SZTURZ, Petr, Zdeněk ADAM, Zdenek REHAK, Renata KOUKALOVÁ, Leoš KŘEN, Mojmír MOULIS, Marta KREJČÍ and Jiří MAYER. Salvage lenalidomide in four rare oncological diseases. \textit{Tumori}. Roma: PENSIERO SCIENTIFICO EDITOR, 2013, vol.~99, No~5, p.~''e251''-''e256'', 6 pp. ISSN~0300-8916. Available from: https://dx.doi.org/10.1700/1377.15326.
|
